Funding
← Back to your selection

Time BioVentures

Activity from announced rounds

All recorded activity
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$335M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series C+1

By primary sector

Biotech2

By country

Australia1
United States1

Rounds

2 in all activity
AdvanCell

AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.

$315MSeries D
Role not disclosed
Waypoint Bio

Develops AI-designed CAR T therapies for solid tumors using spatial biology

$20MSeries A
Role not disclosed